Considering the growing body of evidence demonstrating excellent response of BRAF/MEK inhibitors in tumors with this mutation, the decision to initiate therapy with dabrafenib/trametinib rather than to pursue radiotherapy (RT) was made by the tumor board. The gene discussed is BRAF; the disease is neoplasm.